GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Envoy Medical Inc (NAS:COCH) » Definitions » Common Stock

Envoy Medical (Envoy Medical) Common Stock : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Envoy Medical Common Stock?

Envoy Medical's quarterly common stock stayed the same from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) and stayed the same from Dec. 2023 ($0.00 Mil) to Mar. 2024 ($0.00 Mil).

Envoy Medical's annual common stock declined from Dec. 2021 ($1.39 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).


Envoy Medical Common Stock Historical Data

The historical data trend for Envoy Medical's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Envoy Medical Common Stock Chart

Envoy Medical Annual Data
Trend Dec21 Dec22 Dec23
Common Stock
1.39 - -

Envoy Medical Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Common Stock Get a 7-Day Free Trial Premium Member Only - 1.39 - - -

Envoy Medical Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Envoy Medical (Envoy Medical) Business Description

Traded in Other Exchanges
N/A
Address
4875 White Bear Parkway, White Bear Lake, MN, USA, 55110
Envoy Medical Inc is focused on designing, developing, and marketing fully implantable medical devices that improve hearing. The Company's first commercial product, the Esteem PMA application, is a fully implantable hearing device. The Esteem PMA was cleared in 2010 by the United States Food and Drug Administration. The Company intends to continue to pursue the development of a cochlear implant.